{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:44:39Z","timestamp":1768920279283,"version":"3.49.0"},"reference-count":9,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:p> Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush \u226575-124 mL of intravenous fluid after vinorelbine infusion. In travenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min. <\/jats:p>","DOI":"10.1191\/1078155205jp146oa","type":"journal-article","created":{"date-parts":[[2005,7,15]],"date-time":"2005-07-15T08:12:42Z","timestamp":1121415162000},"page":"79-81","source":"Crossref","is-referenced-by-count":9,"title":["Vinorelbine and venous irritation: optimal parenteral administration"],"prefix":"10.1177","volume":"11","author":[{"given":"M\u00e1rio L","family":"de Lemos","sequence":"first","affiliation":[{"name":"Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, B.C., Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"atypb1","volume-title":"Provincial Systemic Therapy Program Policy III-20: prevention and management of extravasation of chemotherapy","author":"B. C. Cancer Agency Provincial Systemic Therapy Program","year":"2004"},{"key":"atypb2","volume-title":"Navelbine product monograph-product monograph revisions","author":"GlaxoSmithKline","year":"2001"},{"key":"atypb3","first-page":"707","volume":"22","author":"Rittenberg CN","year":"1995","journal-title":"Oncol Nurs Forum"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1007\/s005200000190"},{"key":"atypb5","first-page":"397","volume":"26","author":"Ginopoulos P","year":"1998","journal-title":"Med Sci Res"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-003-0479-z"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.046"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.068"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.8117"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/1078155205jp146oa","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/1078155205jp146oa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:08:00Z","timestamp":1741064880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1191\/1078155205jp146oa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1191\/1078155205jp146oa"],"URL":"https:\/\/doi.org\/10.1191\/1078155205jp146oa","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}